Le Lézard
Classified in: Health, Science and technology
Subject: FVT

University of Maryland Surgical Team Who Conducted Historic Xenotransplantation to Speak in Plenary Session at HFSA Annual Scientific Meeting 2022


ROCKVILLE, Md., Aug. 11, 2022 /PRNewswire/ -- In January 2022, a team of University of Maryland School of Medicine (UMSOM) surgeon-scientists successfully implanted a genetically modified pig heart into a 57-year-old patient with end-stage heart failure, making history and drawing worldwide attention. The patient survived for two months following the first-of-its-kind surgery, which was performed at the University of Maryland Medical Center. The results of this groundbreaking xenotransplant surgery will be discussed in detail during the Monday Plenary Session Cardiac Xenotransplantation: Where we are and where we are going at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) on Monday, October 3, 2022.

The session features these outstanding physicians and scientists:

The session will explore the scientific advances that laid the groundwork for this innovative surgery to occur, clinical translation of xenotransplant, detailed case review of the first successful human heart xenotransplant, and broad discussions of the future for xenotransplantation including clinical potential, challenges, ethical considerations, and other concepts clinicians and researchers need to know for future heart failure care.

"We are absolutely thrilled to have the team behind one of the most innovative, and groundbreaking cardiovascular achievements be able to share this with us at ASM," said David Lanfear, MD, MS, ASM Program Chair and Head of Advanced Heart Failure and Transplantation at Henry Ford Hospital. "Their incredible work is paving the way to a future of adequate access to heart transplantation for all patients. I foresee this being one of our most popular and highly anticipated sessions at ASM."

Drs. Fedson, Griffith, Joseph, and Mohiuddin will be joined by HFSA ASM Program Co-Chairs, Drs. Daniel Garry, MD, PhD, and Cheryl Westlake, PhD, RN, who will moderate the panel discussion within the session.

The HFSA Annual Scientific Meeting will take place September 30-October 3, 2022, at the Gaylord National Harbor, just outside of Washington, DC. This year's meeting will include three plenary sessions, held in the mornings to kick-off each day of programming. Registration for the meeting is open and an advance program is available to download. Learn more about the meeting and register at hfsa.org/asm2022.

PHOTOS

Download speaker photos online at https://hfsa.org/university-maryland-surgical-team-who-conducted-historic-xenotransplantation-speak-plenary-session 

About the Heart Failure Society of America

The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org.

Media Contact: Laura Poko, 301-798-4493, ext. 226, [email protected]

SOURCE Heart Failure Society of America


These press releases may also interest you

at 23:05
OKX, a leading Web3 technology company, today announced the integration of Biturbo with the OKX Wallet. Bitrubo is an innovative layer 2 solution that brings the power of Ethereum's smart contracts to the Bitcoin network. Biturbo is designed as an...

at 23:03
The report titled "Cognitive Security Market by Component (Services, Solutions), Security Type (Application, Cloud, Cybersecurity), Application, Deployment Mode, Enterprise Type, Vertical - Global Forecast 2024-2030" is now available on...

at 22:03
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 20:15
The partnership was unveiled internally at the Franchisor's annual convention in Las Vegas, NV in December 2023, eliciting...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...



News published on and distributed by: